Summary
The Immuno-Oncology Program (IO) established in 2021 unites basic, translational and clinical research scientists from the various disease site programs to address the urgent need to discover novel cancer immunobiologic processes that can be exploited to develop safer, more effective immunotherapies for cancer patients. Through targeted recruitment and engagement of investigators in other CCSG Research Programs and DCI Disease Groups who pursue IO research, we have enabled a comprehensive program of IO discovery and translation. IO is comprised of 54 full members from 8 departments and 2 schoo
